Introduzca una acción o criptomoneda en el cuadro de búsqueda para obtener un resumen
Sensorion SA
RFMSensorion SA, a biotechnology company, develops drug candidates for the treatment of inner ear disorders in France. Its pipeline includes various products in the development stage for restoring, treating, and preventing inner ear related disorders. The company's product portfolio includes SENS-401 SSNHL, which has completed Phase 2 clinical trial for the treatment of Sudden Sensorineural Hearing Loss; SENS-401 CIO that is in Phase 2 clinical trial for the treatment of Cisplatin-Induced Ototoxicity; and SENS-401 Cochlear, which is in Phase 2 clinical trial for the treatment of hearing preservation after cochlear implantation. It is also developing OTOF-GT (SENS-501), a gene therapy development program that has completed Phase 1 clinical trial to restore hearing in people living with Otoferlin deficiency; and GJB2-GT, a gene therapy development program, which is in pre-clinical trial to restore hearing in people living with hearing loss due to mutations in the GJB2 gene. The company was incorporated in 2009 and is headquartered in Montpellier, France. Address: 375, rue du Professeur Joseph Blayac, Montpellier, France, 34080
Analytics
Precio Objetivo de WallStreet
1.76 EURRelación P/E
–Rentabilidad por dividendo
–Año en curso
Año anterior
Trimestre actual
Último trimestre
Año en curso
Año anterior
Trimestre actual
Último trimestre
Cifras clave RFM
Análisis de dividendos RFM
Aumento del dividendo durante 5 años
–Crecimiento continuo
–Ratio de pago medio en 5 años
–Tendencia del payout RFM
Valoración de la acción RFM
Finanzas RFM
Realice un seguimiento de las métricas clave de cada acción en un solo lugar y sin complicaciones
Hazte premiumResultados | 2019 | Dinámica |